1. Home
  2. TTEK vs CINGW Comparison

TTEK vs CINGW Comparison

Compare TTEK & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TTEK
  • CINGW
  • Stock Information
  • Founded
  • TTEK 1966
  • CINGW N/A
  • Country
  • TTEK United States
  • CINGW United States
  • Employees
  • TTEK N/A
  • CINGW 13
  • Industry
  • TTEK Military/Government/Technical
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • TTEK Consumer Discretionary
  • CINGW Health Care
  • Exchange
  • TTEK Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • TTEK N/A
  • CINGW N/A
  • IPO Year
  • TTEK 1991
  • CINGW 2021
  • Fundamental
  • Price
  • TTEK $40.90
  • CINGW $0.04
  • Analyst Decision
  • TTEK Buy
  • CINGW
  • Analyst Count
  • TTEK 4
  • CINGW 0
  • Target Price
  • TTEK $48.70
  • CINGW N/A
  • AVG Volume (30 Days)
  • TTEK 2.8M
  • CINGW N/A
  • Earning Date
  • TTEK 11-13-2024
  • CINGW N/A
  • Dividend Yield
  • TTEK 2.83%
  • CINGW N/A
  • EPS Growth
  • TTEK 20.59
  • CINGW N/A
  • EPS
  • TTEK 1.23
  • CINGW N/A
  • Revenue
  • TTEK $4,321,862,000.00
  • CINGW N/A
  • Revenue This Year
  • TTEK $10.00
  • CINGW N/A
  • Revenue Next Year
  • TTEK $8.33
  • CINGW N/A
  • P/E Ratio
  • TTEK $33.30
  • CINGW N/A
  • Revenue Growth
  • TTEK 15.22
  • CINGW N/A
  • 52 Week Low
  • TTEK $30.92
  • CINGW N/A
  • 52 Week High
  • TTEK $51.20
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • TTEK 29.98
  • CINGW N/A
  • Support Level
  • TTEK $39.91
  • CINGW N/A
  • Resistance Level
  • TTEK $42.15
  • CINGW N/A
  • Average True Range (ATR)
  • TTEK 1.73
  • CINGW 0.00
  • MACD
  • TTEK -0.86
  • CINGW 0.00
  • Stochastic Oscillator
  • TTEK 7.79
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: